A detailed history of Birchview Capital, LP transactions in Karyopharm Therapeutics Inc. stock. As of the latest transaction made, Birchview Capital, LP holds 469,832 shares of KPTI stock, worth $366,468. This represents 0.36% of its overall portfolio holdings.

Number of Shares
469,832
Previous 469,832 -0.0%
Holding current value
$366,468
Previous $408,000 4.66%
% of portfolio
0.36%
Previous 0.41%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

SELL
$0.72 - $1.66 $73,440 - $169,320
-102,000 Reduced 17.84%
469,832 $709,000
Q3 2023

Nov 14, 2023

BUY
$1.14 - $1.81 $319,770 - $507,705
280,500 Added 96.28%
571,832 $766,000
Q4 2022

Feb 03, 2023

BUY
$2.48 - $5.93 $54,560 - $130,460
22,000 Added 8.17%
291,332 $991,000
Q1 2022

May 13, 2022

BUY
$5.91 - $14.38 $137,892 - $335,514
23,332 Added 9.48%
269,332 $1.99 Million
Q3 2021

Nov 12, 2021

BUY
$4.45 - $10.63 $71,200 - $170,080
16,000 Added 6.96%
246,000 $1.43 Million
Q1 2021

May 14, 2021

BUY
$9.85 - $17.69 $413,700 - $742,980
42,000 Added 22.34%
230,000 $2.42 Million
Q4 2020

Feb 09, 2021

BUY
$14.15 - $17.19 $283,000 - $343,800
20,000 Added 11.9%
188,000 $2.91 Million
Q2 2020

Aug 10, 2020

BUY
$16.6 - $25.25 $332,000 - $505,000
20,000 Added 13.51%
168,000 $3.18 Million
Q1 2020

May 12, 2020

BUY
$14.38 - $27.72 $977,840 - $1.88 Million
68,000 Added 85.0%
148,000 $2.84 Million
Q4 2019

Feb 12, 2020

BUY
$9.23 - $19.67 $92,300 - $196,700
10,000 Added 14.29%
80,000 $1.53 Million
Q4 2018

Feb 06, 2019

BUY
$8.2 - $16.95 $164,000 - $339,000
20,000 Added 40.0%
70,000 $656,000
Q2 2018

Aug 02, 2018

BUY
$12.0 - $19.88 $600,000 - $994,000
50,000 New
50,000 $850,000

Others Institutions Holding KPTI

About Karyopharm Therapeutics Inc.


  • Ticker KPTI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 79,806,600
  • Market Cap $62.2M
  • Description
  • Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and in...
More about KPTI
Track This Portfolio

Track Birchview Capital, LP Portfolio

Follow Birchview Capital, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Birchview Capital, LP, based on Form 13F filings with the SEC.

News

Stay updated on Birchview Capital, LP with notifications on news.